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Summary
BACKGROUND: Trastuzumab (Herceptin®, Roche) has
significantly improved the prognosis of patients with
HER2-positive metastatic breast cancer. Some patients re-
main in remission for many years. However, there are no
prognostic markers associated with long-term survival.
This study aimed to analyse treatment patterns of
HER2-positive metastatic breast cancer at a single institu-
tion and explore prognostic factors for long-term survival
after HER2-targeted treatment.
PATIENTS AND METHODS: This was a retrospective co-
hort study of all patients with HER2-positive metastatic
breast cancer receiving first-line treatment with
HER2-targeted therapy between 2004 and 2014 at the
University Hospital of Zurich (n = 81). Overall survival
(OS) and other time-to-event endpoints were determined
with Kaplan-Meier curves and clinicopathological factors
predicting long-term outcome were identified by use of the
log-rank test.
RESULTS: The median OS for the cohort was 5.9 years
(95% confidence interval [CI] 3.5–8.3). Twenty patients
(28.6%) remained in complete remission after 1 year, 11
(15.7%) after 2 years and 4 (5.7%) beyond 5 years. The
median progression-free survival was 13.6 months (95% CI
9.0–18.3). The objective response rate (ORR) was 60.5%
with 16 (19.8%) complete responses and 33 (40.8%) partial
responses. Six (7.4%) patients had brain metastases as first
site of relapse and they had a median OS of 1.9 years (95%
CI 1.7–2.2 years). Thirty-four of all 81 patients (42%) had
developed brain metastases by the time of death or last
follow-up. Median OS after diagnosis of brain metastases
was 26 months (95% CI 19.9–32.0). Only primary brain
metastases were found to be a prognostic marker associated
with shorter overall survival. Hormone-receptor status and
presence of visceral metastases at primary diagnosis were
not associated with prognosis. Only four patients (4.9%)
developed some degree of left ventricular dysfunction un-
der treatment with trastuzumab.
CONCLUSIONS: HER2-targeted treatment has improved
the overall survival of patients with HER2-postive meta-
static breast cancer with median OS exceeding 5 years.
There are, however, no predictive markers for a long-term
survival. Only the absence of primary brain metastases
seems to be an indicator of a good prognosis.
Clinical trial number: SNCTP000001431
Key words: metastatic breast cancer; HER2-positive; anti-
HER2-targeted treatment; prognostic factor; long-term
outcome
Introduction
Treatments targeting the human epidermal growth factor
receptor 2 (HER2) have drastically changed the natural dis-
ease course of HER2-positive breast cancer, particularly
in the presence of metastases [1–3]. HER2 gene amplific-
ation is found in about 15 to 20% of breast cancers and
was associated with poor prognosis before the advent of
HER2-targeted treatments [2, 4].
Trastuzumab, the first humanised monoclonal antibody
against the extracellular domain of HER2 [5], inhibits the
growth of breast tumour cells by receptor internalisation,
inhibition of cell-cycle progression and recruitment of
immune-effector cells [6]. Trastuzumab has been approved
for the treatment of HER2-overexpressing metastatic breast
cancer [6] since 1998 in the United States and since 2000 in
Switzerland and the European Union. A Cochrane collab-
oration study in 2014 on “trastuzumab-containing regimens
for metastatic breast cancer” analysed seven randomised
trials (1497 patients) and showed longer overall surviv-
al and progression-free survival in HER2-positive women
with metastatic breast cancer receiving a trastuzumab treat-
ment regimen [7]. Overall survival has even been shown to
be superior in oestrogen receptor (ER) negative disease [3].
Moreover, patients with ER-positive/HER2-positive breast
cancer have shown the longest survival after diagnosis of
distant metastases among all breast cancer subtypes [8].
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At present, there is no evidence that treatment with trastu-
zumab can safely be stopped after a certain time [9]. The
practical guideline of the American Society of Clinical On-
cology in 2014 recommends HER2-targeted therapy until
progression or significant toxicities [10]. The resultant high
costs of the therapy and possible adverse effects on the car-
diovascular system show the need for more data on this
subject [11]. Some authors have reported stopping trastuzu-
mab maintenance after several years of complete remission
[12, 13]. Knowledge of prognostic factors could optimise
treatment approaches and guide prognostication for this the
population of long-term responders.
Some case reports have described complete remission of
patients with HER2-positive metastatic breast cancer
treated with trastuzumab in combination with chemother-
apy [12]. The longest relapse-free time mentioned was 8.5
years [9]. All of these cases had continued anti-HER2
maintenance therapy. Many were associated with liver
metastases [11, 14], whereas early central nervous system
(CNS) metastases are related to an unfavourable prognosis
[15]. It is also hypothesised that the impact of trastuzumab
in patients with ER-negative disease is higher than in pa-
tients with ER mutation [16]. Cross-talk between activation
of epidermal growth factor / HER2 and ER activation
seems to play a role in resistance to hormonal therapy
[14]. Combination therapy with anti-HER2 agents and en-
docrine treatment offers only limited clinical benefit [17].
However, only a few biomarkers or clinicopathological
predictive factors for overall survival are known to date.
Material and methods
This study was approved by the Ethics Committees of
Zurich and registered at the Swiss National Clinical Trials
Portal (SNCTP000001431) and on clinical trials.gov
(NCT02560311).
Patients
This was a retrospective single-centre cohort study. In-
cluded were all patients treated for HER2-positive meta-
static breast cancer between January 2004 and August 2014
at the University Hospital of Zurich, Switzerland. Patients
receiving prior trastuzumab in the neoadjuvant or adjuvant
setting were not excluded.
All patients were identified using the clinical database.
Clinical follow-up data were recorded up to October 2015.
Each patient’s medical record was reviewed to create a
database of demographic and clinical characteristics. His-
tological information about the primary breast cancer tissue
was taken. HER2 positivity was determined as a grade 3+
in immunohistochemistry or by a positive result of fluor-
escence in situ hybridization (value ≥2.0). ER and proges-
terone receptor (PR) status were documented as described
in the pathology report. Cardiac toxicity was defined as
the occurrence of left ventricular dysfunction of grade 2 or
higher (as defined by the National Cancer Institute [NCI]
version 3.0), confirmed on echocardiogram.
Study endpoints
The primary endpoint of the study was progression-free
survival (PFS), defined as the time from diagnosis of meta-
static breast cancer to the time of disease progression or
death from any cause. Secondary endpoints were overall
survival (OS) and response rate. Response rates were de-
termined with fluordeoxyglucose-positron emission tomo-
graphy, positron emission tomography / computed tomo-
graphy, or computed tomography performed after the first-
line chemotherapy. Criteria for progression or response
were based on an interdisciplinary tumour board decision
that considered imaging, tumour marker and clinical as-
sessment.
For patients who had not reached the endpoint under con-
sideration at the time of the analysis, time-points were cen-
sored at the time of last tumour assessment for PFS and at
the time of last contact for the overall survival OS.
Statistical analysis
Descriptive statistics were used for patient characteristics,
tumour characteristics and details of the received therapy.
Overall survival and other time-to-event endpoints were
evaluated using Kaplan-Meier curves. To evaluate factors
predicting long-term outcomes, the log-rank (Mantel-Cox)
test was used to calculate the hazard ratio (HR) and p-val-
ues.
Results
Patient demographics
A total of 81 patients with HER2-positive metastatic breast
cancer were identified in the hospital’s clinical database
for further analysis. Patients and tumour characteristics are
shown in table 1. The median age at the diagnosis of meta-
static disease was 52 years (range 32–85 years). The me-
dian follow-up duration was 2.9 years (range 0.03–11.46
years) from the time of metastatic breast cancer diagnosis
to death, loss to follow up or cut-off point. At the time of
the last follow-up, 36 deaths (44.4%) were confirmed.
Twenty-six patients (32.1%) had primary (de novo) meta-
static disease. Of the remaining 55 patients with secondary
(not de novo) metastatic breast cancer, 3 had only neoad-
juvant, 7 neoadjuvant plus adjuvant and 45 only adjuvant
therapy. Twenty-five patients had trastuzumab-based ther-
apy, mostly in combination with an anthracycline and a tax-
ane, 30 patients had chemotherapy or endocrine therapy
without an anti-HER2 treatment owing to lack of approval
of trastuzuamb for adjuvant use. The median time from ini-
tial breast cancer diagnosis to diagnosis of metastatic dis-
ease was 3.4 years (range 0.17–13.40 years).
The median number of initial sites of metastatic disease
was two (range one to four). Bone (40 patients, 49.4%) was
the most common site, followed by the liver (36 patients,
44.4%) and nodal metastases (29 patients, 35.8%). Only 6
patients (7.4%) had CNS involvement at first diagnosis of
metastatic disease.
Treatment
As first-line therapy, most patients were treated with trastu-
zumab (69 patients, 86.3%) as anti-HER2 treatment, in
combination with chemotherapy. Five patients received
lapatinib (6.3%) plus chemotherapy. The chemotherapy
most commonly consisted of docetaxel (51.4%) or vinorel-
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bine (33.8%). The other agents used were capecitabine
(10.8%), anthracycline (2.7%) and gemcitabine (1.4%).
The remaining seven patients received either trastuzumab
as monotherapy (two patients, 2.4%), or trastuzumab in
combination with endocrine therapy (five patients, 6.2%).
After disease progression most patients received trastu-
zumab in combination with chemotherapy: second-line in
37 patients (71.2%), third-line in 25 patients (71.4%). As
second-line therapy Trastuzumab was combined with a
newer anti-HER2 therapy for five patients as second-line
therapy and for six patients as third-line therapy. The re-
maining patients received either lapatinib plus chemother-
apy or chemotherapy only (table 1).
Primary brain metastases
Only six (7.4%) patients were found to have brain meta-
stases at first diagnosis of metastatic disease. However,
34 of 81 patients (42%) developed brain metastases at
some point during follow-up. Almost all of these 34 pa-
tients (91.2%) received brain radiotherapy. The treatment
of brain metastases and leptomeningeal spread is summar-
ised in table 2. Median OS after diagnosis of brain meta-
stases was 26 months (95% CI 19.9–32.0 months). The OS
for patients with de novo brain metastases was 1.9 years
(95% CI 1.7–2.2 years).
Response rate of the first therapy
The objective response rate (ORR) was 60.5%, with 16
(19.8%) complete responses and 33 (40.7%) partial re-
sponses (table 3). Four patients had a stable disease and 28
had progressive disease on anti-HER2 treatment.
Outcome
The median OS for all 81 patients was 5.90 years (95% CI
3.5–8.3; Fig. 1a). Median PFS) for the 70 patients avail-
able for analysis was 13.6 months (95% CI 9.0–18.3; Fig.
1b). Twenty patients (28.6%) remained in remission after 1
year, 11 (15.7%) after 2 years and 4 (5.7%) beyond 5 years.
In patients with primary (de novo) metastases the PFS was
25 months (95% CI 16.8–33.2 months), whereas patients
with secondary metastases had a PFS of 11.4 months (95%
CI 7.8–15.0 months; Fig. 1c). The difference between these
two patient groups was significant with a p-value of 0.006.
There was no significant difference between the PFS of pa-
tients with positive hormone receptor status (17.1 months,
95% CI 12.0–22.4) compared with hormone receptor-neg-
ative patients (11.0 months, 95% CI 8.4–9.4; p = 0.77).
Cardiac toxicity
Left ventricular dysfunction during trastuzumab treatment
occurred in four patients (4.9%). Three of them had grade
3 dysfunction and one grade 2 dysfunction. Three of these
patients had received prior anthracycline therapy during
adjuvant treatment.
Predicting long-term responders to trastuzumab
The univariate analysis (table 4) showed no statistically
significant difference in the OS by the time of initial dia-
gnosis (before/after 2009), by hormone receptor status, or
primary versus secondary disease. CNS metastases as first
site of recurrence were significantly associated with a
shorter median OS of 1.9 years (CI 1.7–2.2 years, p = 0.04)
compared with patients with liver metastases (4.6 years,
95% CI 3.6–5.7) or bone metastases only (7.1 years, 95%
CI 0.0–14.7) (Fig. 2a). In patients with first remission dur-
a
b
c
Figure 1
Kaplan-Meier curves for (a) overall survival for all patients, (b)
progression-free survival (n = 70), and (c) progression-free survival
of patients with primary metastatic disease vs patients with
secondary metastatic disease, p = 0.006.
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Table 1: Patients’ characteristics (n = 81).
Age at diagnosis of MBC (years), median (range) 52 (32–85)
Menopausal status
Premenopausal 29 (35.8%)
Postmenopausal 42 (51.9%)
Data missing 10 (12.3%)
Disease status
De novo (primary) 26 (32.1%)
Not de novo (secondary) 55 (67.9%)
Therapy
Neoadjuvant only 3
Neoadjuvant + adjuvant 7
Adjuvant only 45
Tumour stage (n = 77)
I 9 (11.7%)
II 13 (16.9%)
III 19 (37.7%)
IV 26 (33.8%)
Tumour grade (n = 64)
G 2 16 (25%)
G 3 48 (75%)
ER/PR status
ER+/PR+ 32 (39.5%)
ER+/PR− 20 (24.7%)
ER−/PR− 29 (35.8%)
Prior adjuvant therapy (n = 55)
Trastuzumab-based (n = 25)
Anthracycline + taxane 15 (25%)
Anthracycline 2 (3.6%)
Other chemotherapy 1 (1.8%)
Anti-HER2 alone 6 (11.0%)
Anti-HER2 + endocrine 1 (1.8%)
Without anti-HER2 treatment (n = 30)
Anthracycline+ docetaxel 7 (12.7%)
CMF1 6 (10.9%)
Anthracycline 7 (12.7%)
Other chemotherapy 3 (5.4%)
Endocrine alone 7 (12.7%)
Time to first metastatic relapse (years, n = 52)
Mean 3.8
Median(range) 3.4 (0.17–13.40)
Number of site(s) of initial recurrence
1 42 (51.9%)
2 25 (30.9%)
3 12 (14.8%)
4 2 (0.2%)
Site of first metastatic disease2
Liver 36 (44.4%)
Lung 20 (24.7%)
Bone 40 (49.4%)
Brain 6 (7.4%)
Lymph nodes 29 (35.8%)
Skin 1 (1.2%)
Medulla 1 (1.2%)
Soft tissue 3 (3.7%)
First-line treatment of metastatic disease
Trastuzumab + chemotherapy3 69 (86.3%)
Trastuzumab + endocrine (no chemotherapy) 5 (6.3%)
Trastuzumab only4 2 (2.5%)
Lapatinib + chemotherapy5 5 (6.3%)
First-line chemotherapy with anti-HER2 treatment (n = 74)
Vinorelbine 25 (33.8%)
Docetaxel 38 (51.4%)
Anthracycline 2 (2.7%)
Gemcitabine 1 (1.4)
Capecitabine 8 (10.8%)
Anti-HER2 treatment after progression
Original article Swiss Med Wkly. 2016;146:w14393
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 4 of 10
Second-line treatment (n = 52)
Trastuzumab + chemotherapy
(incl. 5 + Pertuzumab, Trastuzumab-Emtansin)
37 (71.2%)
Lapatinib + capecitabine 8 (15.4%)
Trastuzumab-entamsin only 1 (1.9%)
Chemotherapy only
(1 doxorubicin, 2 capecitabine, 2 vinorelbine 1 cyclophosphamide)
6 (11.5%)
Third-line treatment (n = 35)
Trastuzumab + chemotherapy
(incl. 6 + Pertuzumab, Trastuzumab-Emtansin)
25 (71.4%)
Lapatinib + capecitabine 3 (8.6%)
Trastuzumab-entamsin only 3 (8.6%)
Chemo only
(1 doxorubicin, 1 capecitabine, 1 gemcitabine, 1 docetaxel)
4 (11.4%)
ER = oestrogen receptor; MBC = metastatic breast cancer; PR = progesterone receptor; 1 Cyclophosphymide, methotrexate, 5-fluorouracil; 2 Multiple sites can apply; 3 3 plus pertuzumab, 2
plus lapatinib; 4 1 plus lapatinib, 1 intrathecal application; 5 All with capecitabine
ation of ≥2 years, liver metastases were not associated with
a longer survival, compared with other sites of metastasis.
The OS was significantly shorter in patients with first re-
mission duration of <2 years (3.1 years, 95% CI 2.1–4.1)
compared with ≥2 years (7.1 years, 95% CI 6.9–7.3; p =
<0.001) (Fig. 2b).
Discussion
Trastuzumab in combination with chemotherapy comprises
the standard first-line treatment of HER2-positive metastat-
ic breast cancer and has significantly improved prognos-
is of these patients over the last decade. Some patients
have been shown to remain in remission for many years;
however owing to limited published data on long-term re-
mission, only few clinical predictive factors are known.
In this retrospective cohort study, the OS was 5.9 years,
which is higher than in other comparable retrospective ana-
lyses (table 5). This difference might be explained by the
fact that this analysis included patients treated up to 2014,
who might have received newer anti-HER2 treatments and
modern regimens of chemotherapy distribution. Newer
HER2-targeted substances such as pertuzumab,
trastuzumab-emtansin and lapatinib have influenced the
outcome of HER2-positive metastatic breast cancer, as
shown in various studies including the CLEOPATRA trial
[22, 23].
The median PFS in this cohort was 13.6 months, which
is slightly higher than in other studies. There was no dif-
ference between the OS of patients with primary meta-
stases and OS of patients with secondary metastases, but
the group with primary metastases had a longer PFS (25
vs 11.4 months, p = 0.006). An explanation could be that
patients receiving chemotherapy and/or trastuzumab in the
adjuvant setting may not respond as well to the first-line
treatment of metastatic disease as chemotherapy-naive pa-
tients.
This study was able to show that patients with the brain
as first site of recurrence have a significantly shorter me-
dian OS than patients with metastases elsewhere. Brain
metastases in HER2-positive breast cancer are common
and difficult to treat. The 10-year cumulative incidence
for the development of CNS metastases is about 6.8% in
HER2-positive and 3.5% in HER2-negative disease [24],
which might be due to a biological predisposition [15] or
the limited ability of trastuzumab to penetrate the blood-
Table 2: Treatment of patients with brain metastases (n = 34).
Treatment1 Patients
n (%)
Trastuzumab intrathecal2 3 (8.8%)
Lapatinib 14 (41.2%)
Brain radiotherapy 31 (91.2%)
Dexamethason 7 (20.6%)
Brain surgery 5 (6.2%)
No specific treatment 2 (5.8%)
1 Multiple treatments can apply
2 For leptomeningeal spread
Table 3: Best overall response rate.
Therapy n CR PR SD PD ORR (CR+PR)
Trastuzumab + chemotherapy 66 14
(21.2%)
28
(34.6%)
4
(4.9%)
20
(24.7%)
42
Trastuzumab + endocrine
(no chemotherapy)
5 0 3 0 2 3
Trastuzumab only 2 0 0 0 2 0
Trastuzumab + Pertuzumab 3 1 2 0 0 3
Lapitinib + chemotherapy 5 1 0 0 4 1
Total 81 16
(19.8%)
33
(40.8%)
4
(4.9%)
28
(34.5%)
49
(60.5%)
CR = complete response; ORR = objective response rate; PD = progressive disease; PR = partial response, SD = stable disease
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brain barrier as a result of its high molecular weight [11, 25,
26]. However, Dijkers et al. showed that trastuzumab can
target brain lesions because of a disruption of the blood-
brain barrier at the site of the metastasis [27]. The newer
HER2-targeted oral tyrosine kinase inhibitor lapatinib is
smaller and seems to have a better effect on brain meta-
stases [28]. Lapatinib in combination with capecitabine has
been shown to prolong time to progression and OS [29]. In
our cohort, 42.4% of the patients with brain metastases had
received lapatinib.
Other retrospective analyses have tried to find predictors of
long-term outcome (table 5). Olson et al. reported that brain
metastases and duration of first remission are prognostic
factors [18]. Murthy et al. showed that hormone receptor
status is a predictive factor [13].
Witzel et al. analysed patients who had non-progressive
disease for at least 2 years [30]. They showed a positive
association between longer time to progression and age
at initiation of trastuzumab treatment (age less than 50
years), good performance status (Eastern Cooperative On-
a
b
Figure 2
Kaplan-Meier curves of overall survival for (a) brain metastases as
first site of recurrence vs other sites, p = 0.043 and (b) duration of
first remission <2 years vs ≥2 years, p <0.001.
cology Group score 0) and initial response to trastuzumab
treatment (complete remission). Furthermore, they demon-
strated that therapy cessation or interruption should be
avoided as it results in a shorter time to progression. Gene
expression studies have shown that the HER2-enriched in-
trinsic subtype has a higher response rate than HER2 tu-
mours of the luminal intrinsic subtype [31]. More data
on the question of clinicopathological predictors or poten-
tial biomarkers for long-term outcome is necessary to im-
prove treatment approaches. Based on the currently avail-
able evidence, therapy with trastuzumab should not be
stopped.
The long-term use of trastuzumab raises concerns about ad-
verse effects, most importantly its cardiotoxicity. Given as
a single agent, trastzumab was associated with an incidence
of cardiotoxicity of 1.4% over a follow-up period of 2 years
[32]. In the Cochrane collaboration study of 2014, heart
toxicity was found to be between three and four times more
likely [7]. The risk of the cardiotoxicity seems to be mul-
tifactorial, with a higher risk when trastuzumab is admin-
istered with anthracycline, with pre-existing arterial hyper-
tension or in older patients [33]. In our study, four patients
(4.9%) with left ventricular dysfunction were reported.
There are some potential limitations to this study. First of
all, the retrospective nature of the study leads to some po-
tential biases. Over the last decade chemotherapy distribu-
tion, regimens and HER2-targeted treatments have changed
in a way that may render our cohort nonhomogeneous
and therefore limited the statistical power. Furthermore,
we used a small cohort of 81 patients with HER2-positive
metastatic breast cancer at the University Hospital of
Zurich for our study. For some analyses, the number of pa-
tients might have been too small to allow a robust, statistic-
ally meaningful comparison between different parameters
and patient outcome.
In conclusion, this retrospective cohort study was not able
to identify reliable clinicopathological predictors for long-
term outcome for patients under treatment with anti-
HER2-targeted substances, but showed that the prognosis
of HER2-positive metastatic breast cancer has improved
and will probably continue to improve with the combin-
ation of treatments with newer anti-HER2 substances.
Nevertheless, brain metastases remain a clinical problem
[34] and are associated with a shorter overall survival.
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Menopausal status 0.922
Premenopausal 29 10 5.9 (3.9–7.9)
Postmenopausal 42 22 4.6 (2.2–7.0)
First diagnosis 0.38
Before 2009 39 22 Median not reached
After 2009 42 14 6.4 (4.0–8.9)
ER and/or PR status 0.24
ER+/PR+ or ER+/PR− 52 21 6.7 (5.6–7.9)
ER−/PR− 29 15 3.1 (1.4–4.9)
Disease status 0.175
De novo MBC (primary) 26 9 7.1 (2.0–12.2)
Not de novo MBC (secondary) 55 27 5.9 (3.0–8.7)
Number of site(s) of initial recurrence 0.151
1 42 18 7.1 (4.2–10.0)
2 25 10 4.0 (1.8–6.2)
3 12 6 4.6 (3.7–5.6)
4 2 2 Median was reached
Site(s) of initial recurrence
CNS only 6 4 1.9 (1.7–2.2) 0.04
Bone only 12 4 7.1 (0.0–14.7) 0.88
Liver (10 only liver, 26 + other sites) 36 16 4.6 (3.6–5.7) 0.85
Duration of first remission <0.001
<2 years 49 29 3.1 (2.1–4.1)
≥2 years 21 7 7.1 (6.9–7.3)
Initial response to first-line treatment 0.56
Complete response 17 3 Median was reached
Partial response 31 14 5.9 (2.4–9.4)
CI = confidence interval; CNS = central nervous system; ER = oestrogen receptor; MBC = metastatic breast cancer; OS = overall survival; PR = progesterone receptor
Table 5: Summary of retrospective analyses of HER2-positive metastatic breast cancer.
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Figures (large format)
Figure 1
Kaplan-Meier curves for (a) overall survival for all patients, (b) progression-free survival (n = 70), and (c) progression-free survival of patients
with primary metastatic disease vs patients with secondary metastatic disease, p = 0.006.
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Figure 2
Kaplan-Meier curves of overall survival for (a) brain metastases as first site of recurrence vs other sites, p = 0.043 and (b) duration of first
remission <2 years vs ≥2 years, p <0.001.
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